1st Counsel – Lifestyle
Author:
EvolveImmune Therapeutics
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
April 28, 2026
EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting
April 22, 2026
EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting
April 14, 2026